在器官保存时代的生存：爱尔兰喉癌的最新进展。
Survival in an era of organ preservation: an update on laryngeal cancer in Ireland.
机构信息
Department of Otolaryngology, Head and Neck Surgery, Beaumont Hospital, Beaumont Road, Dublin 9, Ireland.
Royal College of Surgeons in Ireland, Dublin 2, Ireland.
出版信息
Eur Arch Otorhinolaryngol. 2023 Oct;280(10):4587-4595. doi: 10.1007/s00405-023-08055-0. Epub 2023 Jun 16.
BACKGROUND
Laryngeal cancer epidemiology has changed in recent years, with falling incidence observed internationally. Organ preservation therapies have revolutionised management, though some patients may be unsuitable and survival was noted to fall in the 2000s. This study examines trends in laryngeal cancer in Ireland.
METHODS
A retrospective cohort study of National Cancer Registry of Ireland data from 1994 to 2014.
RESULTS
From a cohort of 2651, glottic disease was most common (62%, n = 1646). Incidence rose to 3.43 cases/100,000/year for 2010-2014. 5-year disease-specific survival (DSS) was 60.6% and did not change significantly over time. Overall survival (OS) for T3 disease managed with primary radiotherapy was similar to primary surgery (HR 0.98, p = 0.9). DSS for T3 disease improved with primary radiotherapy (HR 0.72, p = 0.045).
CONCLUSION
Incidence of laryngeal cancer in Ireland rose despite international trends, while survival changed little. Radiotherapy improves DSS for T3 disease but does not improve OS, possibly secondary to poor organ function post-radiotherapy.
背景
近年来，喉癌的流行病学发生了变化，国际上的发病率有所下降。器官保存疗法彻底改变了治疗方法，尽管有些患者可能不适合这种方法，而且在 2000 年代生存率有所下降。本研究检查了爱尔兰喉癌的趋势。
方法
这是一项对爱尔兰国家癌症登记处 1994 年至 2014 年数据的回顾性队列研究。
结果
在 2651 例患者中，声门疾病最常见（62%，n=1646）。发病率上升至 2010-2014 年的每 100,000 人/年 3.43 例。5 年疾病特异性生存率（DSS）为 60.6%，且随时间变化不显著。采用原发放疗治疗的 T3 期疾病的总生存率（OS）与原发手术相似（HR 0.98，p=0.9）。原发放疗可提高 T3 期疾病的 DSS（HR 0.72，p=0.045）。
结论
尽管国际趋势如此，但爱尔兰的喉癌发病率上升，而生存率变化不大。放疗可提高 T3 期疾病的 DSS，但不能提高 OS，可能与放疗后器官功能不良有关。
Zotero 插件